E
Ellen Hollywood
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 34
Citations - 2234
Ellen Hollywood is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Bevacizumab & Cetuximab. The author has an hindex of 16, co-authored 34 publications receiving 2024 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
Leonard B. Saltz,Heinz-Josef Lenz,Hedy L. Kindler,Howard S. Hochster,Scott Wadler,Paulo M. Hoff,Nancy E. Kemeny,Ellen Hollywood,Mithat Gonen,Marcus Quinones,Meroe Morse,Helen X. Chen +11 more
TL;DR: Cetuximab and bevacizumab can be administered concurrently, with a toxicity pattern that seems to be similar to that which would be expected from the two agents alone.
Journal ArticleDOI
Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial
Deborah Schrag,Martin R. Weiser,Karyn A. Goodman,Mithat Gonen,Ellen Hollywood,Andrea Cercek,Diane Reidy-Lagunes,Marc J. Gollub,Jinru Shia,Jose G. Guillem,Larissa K. Temple,Philip B. Paty,Leonard B. Saltz +12 more
TL;DR: For selected patients with clinical stages II to III rectal cancer, neoadjuvant chemotherapy and selective radiation does not seem to compromise outcomes.
Journal ArticleDOI
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
TL;DR: Pharmacokinetic data suggest an increase in the plasma Css in relation to the escalation of FK866, and the recommended phase II dose is 0.126 mg/m2/h given as a continuous 96-h infusion every 28 days.
Journal ArticleDOI
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
L. B. Saltz,Heinz Joseph Lenz,Howard S. Hochster,Scott Wadler,Paulo M. Hoff,Nancy E. Kemeny,Ellen Hollywood,Mithat Gonen,S. Wetherbee,Helen X. Chen +9 more
TL;DR: Cetuximab ( cetux), a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has shown antitumor activity both alone and in combination with irinotecan.
Journal ArticleDOI
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Shukui Qin,Baek-Yeol Ryoo,Sheng-Nan Lu,Sheng-Nan Lu,Chia Jui Yen,Yin-Hsun Feng,H. Y. Lim,Francesco Izzo,Massimo Colombo,Debashis Sarker,Luigi Bolondi,Gina M. Vaccaro,William P. Harris,Z. Chen,Richard A Hubner,Tim Meyer,Weijing Sun,James J. Harding,James J. Harding,Ellen Hollywood,Jennifer Ma,Peter Justin Wan,Michele Ly,John S. Bomalaski,Amanda Johnston,Chen-Chun Lin,Yee Chao,L-T Chen,L-T Chen,L-T Chen +31 more
TL;DR: ADI-PEG 20 monotherapy did not demonstrate an OS benefit in second line setting for HCC, but was well tolerated and Strategies to enhance prolonged arginine depletion and synergize the effect of ADI- PEG 20 are underway.